ADMA Biologics (NASDAQ: ADMA) is a late stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. ADMA's targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. ADMA's three FDA-licensed approved products including ASCENIV™ (Immune Globulin Intravenous - slra, Human), BIVIGAM® (Immune Globulin Intravenous, Human) are intended to be used by physician specialists focused on caring for immune-compromised patients with infectious diseases.

ADMA also operates ADMA BioCenters, an FDA-licensed, GHA-certified source plasma collection facility which provides a portion of blood plasma for the manufacture of its products.

On October 22, 2013 ADMA Biologics announced the closing of its previously announced initial public offering of 3,352,941 shares of its common stock at a public offering price of $8.50 per share.